News · 26 weeks34+400%
2026-04-262026-10-18
Mix1590d
- SEC Filings7(47%)
- Other6(40%)
- Earnings2(13%)
Latest news
25 items- PRPolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026Management to outline ‘PolyPid 2030’, the Company’s long-term vision and pipeline strategy Event to feature Warren S. Joseph, DPM, FIDSA, a nationally recognized specialist in lower extremity infectious diseases Petach Tikva, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it will host a virtual Investor Day on Wednesday, October 28, 2026, at 11:30 a.m. ET. During the event, PolyPid’s management team will outline the Company’s "PolyPid 2030" long-term growth and pipeline strategy. Management will also pro
- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
- PREuropean Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month Validation confirms that the application is complete and EMA initiates formal review of D-PLEX₁₀₀ D-PLEX₁₀₀ NDA concurrently under FDA Priority Review with November 28, 2026 PDUFA goal date PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that the European Medicines Agency ("EMA") has validated the Company’s recently submitted Marketing Authorization Application ("MAA") for D-PLEX₁₀₀, its
- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
- PRPolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization OpportunitiesPETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that PolyPid and ADVANZ PHARMA have mutually agreed to terminate their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe. As a result, the exclusive European commercialization rights for D-PLEX₁₀₀ have reverted to PolyPid. "We appreciate the collaboration with the ADVANZ PHARMA team over the past several years and thank them for working with us to reach a mutually agreeable conclusion," sa
- PRPolyPid Announces Participation in Upcoming Fall Investor ConferencesPETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in the following upcoming investor conferences: 5th Annual ROTH Healthcare Opportunities ConferenceDates: September 29, 2026Location: Metropolitan Club, New York, NYFormat: Panel discussion and one-on-one investor meetingsPanel: "The Biotech Reset: Regulatory Uncertainty, Capital Constraints and the Search for Value," 12:00-12:30 p.m. ET Investors interested in meeting with PolyPi
- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
- SECSEC Form S-8 filed by PolyPid Ltd.S-8 - PolyPid Ltd. (0001611842) (Filer)
- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
- PRPolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsFDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization Partnership with Azurity Pharmaceuticals; $30 Million in Upfront and Near-Term Milestones Achieved Following NDA Acceptance, with Over $290 Million in Additional Milestones Plus Tiered Royalties Up to Mid-Twenties Percentages Potential U.S. Commercial Launch of D-PLEX₁₀₀ by Azurity Targeted for Early 2027 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmac
- PRPolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its second quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 12, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minu
- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
- PRPolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company’s previously communicated guidance FDA identified no Filing review issues Acceptance triggers $15 million milestone payment, completing $30 million in upfront and near-term milestone payments under recently announced U.S. and Canada commercialization partnership PETACH TIKVA, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that the U.S. Food and Drug Administration ("FDA") has accepted for filing the New Drug Application
- SECSEC Form 6-K filed by PolyPid Ltd.6-K - PolyPid Ltd. (0001611842) (Filer)
- PRPolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and CanadaPolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentagesAzurity, a private global pharmaceutical company, to commercialize D-PLEX100 upon approval in the U.S. and Canada for the prevention of surgical site infections, leveraging its first-in-class commercial model. PolyPid to manufacture and supply D-PLEX100Azurity will also fund clinical development of D-PLEX100, supporting the potential label expansion in the U.S. and Canada beyond SSI indications for abdominal surgeryPartnership follows positive Phase 3 SHIELD II results, dem
- INSIDERSEC Form 4 filed by Chief Operating Officer - US Warshavsky Ori4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Missulawin Jonathan4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Deputy CEO, EVP, RD, CRA Hazan Dalit Fellous4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Director Barenholz Yechezkel4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Director Stein Robert Benjamin4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Director Dror-Darwish Nir4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Director Benamram Joseph4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Director Krinsky Itzhak4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Director Story Brooke4 - PolyPid Ltd. (0001611842) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Akselbrad Dikla Czaczkes4 - PolyPid Ltd. (0001611842) (Issuer)
PYPD FAQ
7 questionsWhat does PolyPid Ltd. do?
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Where does PYPD stock trade?
PolyPid Ltd. (PYPD) is listed on NASDAQ.What sector and industry is PYPD in?
PolyPid Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did PolyPid Ltd. go public?
PolyPid Ltd. (PYPD) completed its IPO in 2020.What are analysts saying about PYPD?
PolyPid Ltd. has had 6 recent analyst actions on file. The most recent action was from Roth Capital: Buy with a $900.00 price target on 2025-06-05. Recent price targets range from $900.00 to $2400.00.What companies are similar to PYPD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PYPD side-by-side with any of them on Quantisnow.How can I track PYPD on Quantisnow?
Quantisnow aggregates PolyPid Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PYPD to receive live email and push alerts on every new disclosure.